10 completed, 3 terminated, 1 recruiting. 14 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 14 | Completed 10, Terminated 3, Recruiting 1 |
Follow Filgotinib: new trials by email Literature Review of Filgotinib trials Research Report on Filgotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases Filgotinib - Behcet's Disease, Idiopathic Inflammatory Myopathies | Phase 2 | Recruiting | UMC Utrecht | 60 | 2024-03-12 | 2026-05-12 |
| Study to Evaluate the Effect of Filgotinib on Semen Parameters in Adult Males With Active Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Non-radiographic Axial Spondyloarthritis Filgotinib, Placebo, Standard of Care - Rheumatoid Arthritis, Psoriatic Arthritis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 109 | 2019-05-28 | 2024-04-30 |
| Study to Evaluate the Safety and Efficacy of Filgotinib and Lanraplenib in Adults With Lupus Membranous Nephropathy (LMN) Filgotinib, Lanraplenib, Filgotinib placebo - Lupus Membranous Nephropathy | Phase 2 | Completed | Gilead Sciences | 9 | 2017-10-06 | 2020-05-18 |
| An Open-label, Long-term Extension Study With Filgotinib in Active Psoriatic Arthritis. filgotinib - Psoriatic Arthritis | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 122 | 2017-07-26 | 2022-04-21 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in Adults With Active Noninfectious Uveitis Filgotinib, Placebo to match filgotinib, Prednisone - Noninfectious Uveitis | Phase 2 | Terminated | Gilead Sciences | 74 | 2017-07-26 | 2022-01-21 |
| Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Inflammatory Bowel Disease Filgotinib, Placebo, Standard of Care - Inflammatory Bowel Disease | Phase 2 | Terminated | Lakefront Biotherapeutics NV | 139 | 2017-07-11 | 2024-10-09 |
| Study to Evaluate Safety and Efficacy of Filgotinib and Lanraplenib in Females With Moderately-to-Severely Active Cutaneous Lupus Erythematosus (CLE) Lanraplenib, Filgotinib, Lanraplenib placebo - Cutaneous Lupus Erythematosus | Phase 2 | Completed | Gilead Sciences | 47 | 2017-05-24 | 2020-06-09 |
| Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome Lanraplenib, Filgotinib, Tirabrutinib - Sjogren's Syndrome | Phase 2 | Completed | Gilead Sciences | 152 | 2017-05-01 | 2020-10-23 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD) Filgotinib, Placebo to match filgotinib - Small Bowel Crohn's Disease | Phase 2 | Completed | Gilead Sciences | 78 | 2017-04-11 | 2021-08-23 |
| Study to Evaluate the Efficacy and Safety of Filgotinib in the Treatment of Perianal Fistulizing Crohn's Disease Filgotinib, Placebo to match filgotinib - Fistulizing Crohn's Disease | Phase 2 | Completed | Gilead Sciences | 57 | 2017-04-06 | 2022-04-08 |
| A Study to Assess Efficacy and Safety of Filgotinib in Active Psoriatic Arthritis filgotinib, Placebo Oral Tablet - Psoriatic Arthritis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 131 | 2017-03-09 | 2018-04-23 |
| A Study to Assess Efficacy and Safety of Filgotinib in Ankylosing Spondylitis filgotinib, Placebo Oral Tablet - Ankylosing Spondylitis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 116 | 2017-03-07 | 2018-08-13 |
| Safety, Tolerability, and Efficacy of GS-9876 in Participants With Active Rheumatoid Arthritis on Background Therapy With Methotrexate GS-9876, Filgotinib, GS-9876 placebo - Rheumatoid Arthritis | Phase 2 | Completed | Gilead Sciences | 83 | 2016-09-21 | 2018-09-19 |
| Long-term Follow-up Study of GLPG0634 in Active Rheumatoid Arthritis Participants Filgotinib - Rheumatoid Arthritis | Phase 2 | Completed | Lakefront Biotherapeutics NV | 739 | 2014-02-25 | 2024-06-04 |
Arthritis, Psoriatic (3) · Arthritis, Rheumatoid (3) · Spondylitis, Ankylosing (2) · Behcet Syndrome (1) · Immunoglobulin G4-Related Disease (1) · Inflammatory Bowel Diseases (1) · Lupus Erythematosus, Cutaneous (1) · Myositis (1) · Sjogren's Syndrome (1)
Gilead Sciences (7) · Lakefront Biotherapeutics NV (6) · UMC Utrecht (1)
United States (9) · Poland (8) · Ukraine (8) · Czechia (7) · Spain (7) · Belgium (6) · Bulgaria (6) · Germany (5) · United Kingdom (5) · Canada (4) · Estonia (4) · Australia (3) · Austria (3) · France (3) · Hungary (3)
Pille Harrison, MD, DPhil, MRCP (UK) (2) · Jaap M van Laar, Prof. dr. (1) · Vijay Rajendran, MD (1)
PMID 35614292, PMID 37137672, PMID 30360969, PMID 30360970, PMID 31624837, PMID 33177349, PMID 33380521, PMID 33526618, PMID 34352069, PMID 34498056, PMID 34647992, PMID 35377447, PMID 36205910, PMID 37172783, PMID 37747626, PMID 37945284, PMID 38366672, PMID 39023880, PMID 39884731, PMID 39915014
2016 (4), 2017 (3), 2018 (1)